Matrix Capital Management Company LP

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Matrix Capital Management Company LP
CRD #160066
SEC #801-73612
CIK #0001410830, 0001906866
AUM 2,323.7 M (2026-03-31)
Employees 7 (57% Investors, 0% Brokers)
Fees
Minimum
Phone603-956-9151
Address3 Pleasant Street
Portsmouth, NH 03801
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
151296302010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5 – Fees and Compensation

The fees applicable to each Fund are set forth in detail in each Fund’s governing documents
(“Governing Documents”). Generally, the Firm is paid a fee for its advisory services (the
“Management Fee”). Additionally, the General Partners may receive incentive allocations or
carried interest (as applicable) (“Performance Allocation”).

The Firm may, and has, in its discretion, agreed to waive all or a portion of the Management Fee
with respect to a capital account or, with the consent of the investors, charge a Management Fee
on a different basis or at a different rate. The Firm has the discretion to waive the payment of any
Management Fee or Performance Allocation. The Firm reduces or waives Management Fees
and/or Performance Allocation for certain affiliates and related persons of the Firm, including,
without limitation, limited partners that are employees or partners of the Firm and/or their
immediate family members, and accounts established for the benefit of such persons.

As more fully described in each Fund’s respective Governing Documents, the Funds will generally
bear expenses in connection with their organizational matters and investment activities, in certain
cases subject to an expense cap. The Firm will allocate expenses in accordance with its expense
allocation policies and procedures. Certain expenses are the obligation of a particular Fund and are
borne by such Fund. Conversely, certain expenses relate to more than one Fund and in such
instances are generally allocated among such Funds on a pro rata basis.

Neither Matrix, AyurMaya or any of its supervised persons accept any other forms of
compensation.

A.     Matrix Capital Management Company, LP

Management Fee

Matrix is paid a Management Fee, payable quarterly in advance, with respect to each capital
account. Effective as of January 1, 2025, the Management Fee from the Matrix Funds is equal to
0.25% (1% annualized) of such capital account’s balance. The Management Fee is calculated and
payable as of the first day of each calendar quarter, giving effect to any contributions on that day.
A pro rata Management Fee is assessed on any capital contributions accepted as of any date other
than the first day of the quarter and charged to the capital account of the contributing investor. If
an investor withdraws all or a portion of the balance of a capital account other than on the last
business day of a calendar quarter, Matrix will repay to the Matrix Fund for disbursement to the
withdrawing investor a pro rata portion of the Management Fee charged to such capital account.
Without consent of the investors, the Management Fee may be charged to, and paid by, the Master
Fund, instead of the Feeder Funds.

Performance Allocation

Matrix receives a Performance Allocation generally equal to 20% of realized and unrealized net
profits of each Feeder Fund for each fiscal year; provided, that each such Fund maintains a
bookkeeping account to determine the high-water mark (a “Loss Recovery Account”) that must be
exceeded before the performance-based compensation with respect to an investor in a Matrix Fund
is charged at a rate of 20%. The Loss Recovery Account of each investor in a Matrix Fund
commences at zero. As of each adjustment date, the Loss Recovery Accounts of each Matrix Fund
is either (i) increased by an amount equal to two and one-half times (250%) of any net loss
allocated for such fiscal period or (ii) decreased (but not below zero) by the amount of any net
profit allocated for such fiscal period. An investor will bear a Reduced Performance Allocation
equal to 10% of its realized and unrealized net profits until the balance of its Loss Recovery
Account is reduced to zero, and a Performance Allocation at the 20% rate thereafter. Unless
otherwise determined by Matrix, in the event that a Matrix Fund is terminated or an investor
withdraws or redeems other than at the end of a fiscal year, then for purposes of determining the
applicable Performance Allocation, net capital appreciation will be determined as if such dates
were the end of the fiscal year, subject to certain adjustments.

Effective October 1, 2025, Matrix adopted changing the performance fee from a traditional
"hedge fund" arrangement calculated on the basis of realized and unrealized gains and looses to a

traditional "private equity style" waterfall. The new performance compensation structure will be
a back-ended, European-style waterfall model. Under this structure, Matrix will not receive its
performance compensation (in the form of “carried interest”) until all investors have received (x)
a full return of their capital account balances as of October 1, 2025, and (y) a full recovery of the
Loss Recovery Account calculated as of September 30, 2025, consistent with the methodology
used under the existing hedge fund fee arrangement. Any carried interest distributions will be
subject to an after-tax clawback if, upon the final liquidation of the Fund, Matrix actually
receives carried interest distributions in excess of the carried interest distributions it is entitled to
receive under the distribution waterfall (net of taxes to which Matrix and its members bear in
respect of such carried interest distributions). In addition, to accommodate the Matrix’s
(and its partners’) periodic tax obligations with respect to allocations of income in respect of
carried interest, the Fund will allow the Matrix to receive distributions to cover taxes on such
allocated taxable income. Importantly, the Fund will no longer apply the modified high-water
mark provision in connection with calculating performance compensation. The carried interest
“rate” will be fixed at 10% across all investors. Under the new performance compensation
structure, there will be no preferred return or catch-up provision.

Expenses

Matrix bears its own overhead expenses incurred in connection with managing the Matrix Funds,
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7 – Types of Clients

Matrix and AyurMaya provide investment advisory services to the Matrix Funds and AyurMaya
Fund, respectively. The Funds are formed as partnerships and limited companies in the U.S. and
Cayman Islands. Interests in the Funds were offered pursuant to applicable exemptions from
registration under the Securities Act of 1933 (“Securities Act”) and the 1940 Act. Investors in the
Funds are generally “qualified purchasers” or “knowledgeable employees,” each as defined in the
1940 Act (and rules promulgated thereunder) and may include, among others, U.S. and foreign-
based high net worth individuals, corporations, trusts, institutions, financial institutions, and
government entities. The Matrix Funds and AyurMaya Fund impose a minimum initial investment
of $5 million, which may be waived at the discretion of Matrix and AyurMaya respectively.
Sector Form 13F Holdings Value ($B)
AURA Biosciences Inc 0.0
 
 
 
 
 
 
 
 
 
 
Holdings by Sector ($B)
151296302011201620212027
Type Form D Funds Date Sold AUM
PE Ayurmaya Capital Management Fund LP [2021-12-15] 655.0 M 756.9 M
Filed 2021-12-15 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
HF Matrix Capital Management Fund II LP [2012-02-14] 25.4 M 46.9 M
Filed 2017-03-21 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $50,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Matrix Capital Management Master Fund LP [2012-02-14] 1,327.5 M 1,566.8 M
Filed 2025-03-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Commission $48,138 · Net Assets Decline to Disclose
HF Matrix Capital Management Restricted Investment Fund LP 2012-02-14 10.4 M
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 4 2.3
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 4 2.3
By Discretionary
Discretionary 4 2.3
Non-Discretionary 0 0.0
Total 4 2.3
By Non-United States Persons
Non-United States Persons 0.6
United States Persons 1.7
Total 4 2.3
Form D Directors Role # Filings # Firms 2011 - 2026
Laren Gillespie Director 119 24
Lisa Alexander Director 75 17
Richard Ruffer Director 425 15
Christine Fletcher Director 72 13
Alison Martinson Director 38 13
Gregory Brown Director 31 3
David Goel Director, Executive Officer 13 2
Matrix General Partner LP Executive Officer 2 2
Matrix General Partner LLC Executive Officer 2 2
Ayurmaya General Partner LLC Executive Officer 1 1
Timothy Frechette Director 1 1
Ayur Maya Capital Management Company LP Promoter 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001410830]
3 [0001410830]
4 [0001410830]
SC 13D [0001410830]
SC 13G [0001410830]
13F-HR [0001906866]
Form 13D/13G Filer Form 13D/13G Subject Filed
Matrix Capital Management Company LP Maze Therapeutics Inc [2025-05-14]
Matrix Capital Management Company LP Zentalis Pharmaceuticals Inc [2022-06-03]
Matrix Capital Management Company LP Forgerock Inc [2022-02-14]
Matrix Capital Management Company LP Perimeter Solutions Sa [2022-02-14]
Matrix Capital Management Company LP AURA Biosciences Inc [2021-11-04]
Matrix Capital Management Company LP Bigcommerce Holdings Inc [2021-02-16]
Matrix Capital Management Company LP Zentalis Pharmaceuticals Inc [2021-02-16]
Matrix Capital Management Company LP Altair Engineering Inc [2020-02-14]
Matrix Capital Management Company LP Adaptive Biotechnologies Corp [2020-02-14]
Matrix Capital Management Company LP Cargurus Inc [2019-02-14]
View All
Firm Profile (Form ADV)
Discretionary AUM$1.5B
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI549300CAYJ90YENRRB21
Form 3/4/5 Subject 2011 - 2026
Matrix Capital Management Company LP
Aura Biosciences Inc
GOEL David E
Zentalis Pharmaceuticals Inc
Adaptive Biotechnologies Corp
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
2025-12-15 Sell 7,500,000 $1.33 9,975,000
Aura Biosciences Inc AURA
Common Stock, par value $0.00001 per share (Common Stock)
2023-11-09 Buy 1,560,000 $9.00 14,040,000
Zentalis Pharmaceuticals Inc ZNTL
Common Stock, par value $0.001 per share
2023-06-20 Buy 4,760,000 $22.66 107,861,600
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
2022-12-05 Buy 1,250,000 $12.00 15,000,000
Aura Biosciences Inc AURA
Common Stock
2021-11-02 Buy 1,785,000 $14.00 24,990,000
Aura Biosciences Inc AURA
Series E Convertible Preferred Stock · derivative
2021-11-02 Conversion 2,327,870 $0.00
Aura Biosciences Inc AURA
"Common Stock, par value $0.00001 per share (""Common Stock"")"
2021-11-02 Conversion 2,327,870
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-10 Sell 30,268 $42.38 1,282,758
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-10 Sell 25,732 $41.47 1,067,106
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-09 Sell 34,302 $41.16 1,411,870
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-09 Sell 215,698 $40.42 8,718,513
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 71,194 $41.21 2,933,905
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 234,295 $38.22 8,954,755
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 75,000 $39.22 2,941,500
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 33,600 $39.97 1,342,992
Adaptive Biotechnologies Corp ADPT
Common Stock
2021-03-08 Sell 85,911 $41.62 3,575,616
Adaptive Biotechnologies Corp ADPT
Common Stock
2020-07-20 Sell 2,000,000 $40.00 80,000,000
Adaptive Biotechnologies Corp ADPT
Common Stock
2020-01-24 Conversion 2,217,101 $26.50 58,753,176
Adaptive Biotechnologies Corp ADPT
Common Stock
2019-07-01 Conversion 84,359
Adaptive Biotechnologies Corp ADPT
Series E-1 Convertible Preferred Stock · derivative
2019-07-01 Conversion 5,893,716 $0.00
showing 20 of 26 most recent transactions
Comparable Firms State AUM
Oxford Finance Advisors LLC
VA 2,406.9 M
Irenic Capital Management LP
NY 2,398.7 M
Broadriver Asset Management LP
NY 2,342.3 M
Tiptree Advisors LLC
NY 2,310.8 M
SageView Capital LP
CT 2,307.2 M
Varadero Capital LP
NY 2,292.2 M
Waratah Capital Advisors Ltd
2,271.0 M
Coliseum Capital Management LLC
CT 2,269.4 M
Teng Yue Partners LP
NY 2,247.5 M
Mason Capital Management LLC
NY 2,237.5 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com